Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

被引：15

作者：

Zhang, Jing ^{[1
]}

Romero, Jan ^{[1
]}

Chan, Audrey ^{[1
]}

Goss, Jennifer ^{[1
]}

Stucka, Sabrina ^{[1
]}

Cross, Jason ^{[1
]}

Chamberlain, Brian ^{[1
]}

Varoglu, Mustafa ^{[1
]}

Chandonnet, Haoqun ^{[1
]}

Ryan, Dominic ^{[1
]}

Lippa, Blaise ^{[1
]}

机构：

[1] Cubist Pharmaceut, Lexington, MA 02421 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 17期

关键词：

IBD; Crohn's disease; Ulcerative colitis; CCR9; Sulfonamide; CELLS; LOCALIZATION; LYMPHOCYTES; RECEPTOR;

D O I：

10.1016/j.bmcl.2015.06.046

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：3661 / 3664

页数：4

共 50 条

[21] Functional expression of CCR9 by lung cancer
Singh, Rajesh
Grizzle, William
Lillard, James, Jr.
Singh, Shailesh
JOURNAL OF IMMUNOLOGY, 2011, 186
[22] Intracellular allosteric antagonism of the CCR9 receptor
Oswald, Christine
Rappas, Mathieu
Kean, James
Dore, Andrew S.
Errey, James C.
Bennett, Kirstie
Eflorian, Francesca D.
Christopher, John A.
Jazayeri, Ali
Mason, Jonathan S.
Congreve, Miles
Cooke, Robert M.
Marshall, Fiona H.
NATURE, 2016, 540 (7633) : 462 - +
[23] A novel role for CCR9 in colon cancer
Laffman-Johnson, Elise
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (06) : 674 - 674
[24] Intracellular allosteric antagonism of the CCR9 receptor
Christine Oswald
Mathieu Rappas
James Kean
Andrew S. Doré
James C. Errey
Kirstie Bennett
Francesca Deflorian
John A. Christopher
Ali Jazayeri
Jonathan S. Mason
Miles Congreve
Robert M. Cooke
Fiona H. Marshall
Nature, 2016, 540 : 462 - 465
[25] CCR9 Antagonists in the Treatment of Ulcerative Colitis
Bekker, Pirow
Ebsworth, Karen
Walters, Matthew J.
Berahovich, Robert D.
Ertl, Linda S.
Charvat, Trevor T.
Punna, Sreenivas
Powers, Jay P.
Campbell, James J.
Sullivan, Timothy J.
Jaen, Juan C.
Schall, Thomas J.
MEDIATORS OF INFLAMMATION, 2015, 2015
[26] HLA-DRhi and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD
Linton, Ludvig
Karlsson, Mats
Grundstrom, Jeanette
Hjalmarsson, Eric
Lindberg, Annelie
Lindh, Emma
Glise, Hans
Befrits, Ragnar
Janczewska, Izabella
Karlen, Per
Winqvist, Ola
Eberhardson, Michael
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2012, 3
[27] Phosphodiesterase inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease
Keshavarzian, Ali
Mutlu, Ece
Guzman, Juan P.
Forsyth, Christopher
Banan, Ali
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (09) : 1489 - 1506
[28] CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist
Lee, Sangjun
Heinrich, Eileen L.
Li, Lily
Lu, Jianming
Choi, Audrey H.
Levy, Rachel A.
Wagner, Jeffrey E.
Yip, M. L. Richard
Vaidehi, Nagarajan
Kim, Joseph
MOLECULAR ONCOLOGY, 2015, 9 (08) : 1599 - 1611
[29] Expression and clinical significance of CCR9 in prostate cancer
Singh, Shailesh
Singh, Rajesh
Gupta, Pranav
Lillard, James, Jr.
Grizzle, William
JOURNAL OF IMMUNOLOGY, 2013, 190
[30] A role for CCR9 in T lymphocyte development and migration
Uehara, S
Grinberg, A
Farber, JM
Love, PE
JOURNAL OF IMMUNOLOGY, 2002, 168 (06): : 2811 - 2819

← 1 2 3 4 5 →